This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2024
AMA 2024
ASCO 2024
AUA 2024
APCCC 2024
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Bladder Cancer
Conferences
Recent Abstracts
ASCO 2023: FGFR3 Alterations in PROOF 302: A Phase III Trial of Infigratinib (BGJ398) as Adjuvant Therapy in Patients with Invasive Urothelial Carcinoma
June 4, 2023
ASCO 2023: Efficacy and Safety of Darolutamide in Chinese Patients with mHSPC: A Subpopulation Analysis of the Phase 3 ARASENS Study
June 4, 2023
ASCO 2023: Discussant: Right Treatment, Right Setting for Systemic Therapy
June 4, 2023
ASCO 2023: Discussant: Optimizing Outcomes in Upfront Management of Localized Bladder Cancer
June 4, 2023
ASCO 2023: Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Non-Muscle Invasive BCG Unresponsive Urothelial Carcinoma of the Bladder
June 4, 2023
ASCO 2023: ADVANCED-2: Phase 1b/2 Dose Expansion, Open-Label Study to Evaluate Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade NMIBC
June 4, 2023
ASCO 2023: Discussant: Quality in the Context of Quantity: Evaluating Treatment Intensification
June 4, 2023
ASCO 2023: Long-Term Outcomes of Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
June 4, 2023
ASCO 2023: Primary Analysis of STARTAR: A Phase 2 Salvage Trial of ADT and Apalutamide with Radiation Therapy Followed by Docetaxel in Men with PSA Recurrent Prostate Cancer After Radical Prostatectomy
June 4, 2023
ASCO 2023: ARAMON: A Phase 2, Randomized, Open-Label Study Comparing the Effects of Darolutamide Versus Enzalutamide Monotherapy on Serum Testosterone Levels in Patients with Hormone-Naive Prostate Cancer
June 4, 2023
ASCO 2023: Tumor Factors and the Variation in Non-Muscle Invasive Bladder Cancer Recurrence After Transurethral Resection Surgery Between Sites: Results from the RESECT Study
June 4, 2023
ASCO 2023: Discussant: Looking for Prostate Cancer: Will Novel Imaging Light the Way?
June 4, 2023
ASCO 2023: Pre-Surgical 68Ga-PSMA-11 PET for Biochemical Recurrence Risk Assessment: A Surrogate of Pelvic Lymph Node Dissection? Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial
June 4, 2023
ASCO 2023: PANTHER: A Prospective Trial of Apalutamide and Abiraterone Acetate plus Prednisone in Black and White Men with mCRPC
June 4, 2023
ASCO 2023: Do Bone Scans Over-Stage Disease Compared to PSMA PET? an International Multicenter Retrospective Study with Blinded Independent Readers
June 4, 2023
ASCO 2023: Patient Reported Quality of Life and Survival Outcomes: Analysis of ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED) in Prostate Cancer
June 4, 2023
ASCO 2023: A Study of Prospective Monitoring of Patients with Recurrent Prostate Cancer Using Serial 18F-DCFPyL PSMA Imaging
June 4, 2023
ASCO 2023: Enfortumab Vedotin with or Without Pembrolizumab in Patients Who Are Cisplatin-Ineligible with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer: Additional 3-Month Follow-up on Cohort K Data
June 4, 2023
ASCO 2023: Health-Related Quality of Life and Pain Outcomes for Patients with mCRPC Who Received Abiraterone and Olaparib Vs Abi and Placebo in the Phase III PROpel Trial
June 4, 2023
ASCO 2023: Patient-Reported Outcomes Among Men Receiving Talazoparib + Enzalutamide vs Placebo + ENZA as First-Line Treatment for mCRPC: Results from a Phase 3 Study (TALAPRO-2)
June 4, 2023
Page 57 of 575
Start
Prev
52
53
54
55
56
57
58
59
60
61
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free